Patient info Open main menu

Cefotaxime 500 mg powder for solution for injection – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
500 mg
Contains active substance:
ATC code:

Patient leaflet - Cefotaxime 500 mg powder for solution for injection

1. What Cefotaxime Injection is and what it is used for 2. What you need to know before you use Cefotaxime

Injection

  1. 3. How to use Cefotaxime Injection
  2. 4. Possible side effects
  3. 5. How to store Cefotaxime Injection
  4. 6. Contents of the pack and other information
  5. 1. WHAT CEFOTAXIME INJECTION IS AND WHAT IT IS USED FOR

Cefotaxime Injection is an antibiotic belonging to a group

range of micro-organism. It is used for the treatment of a range of serious bacterial infections of:

  • the lungs (pneumonia)
  • the urinary tract
  • the membranes covering the brain (meningitis) • the abdomen
  • the skin and soft tissue
  • the genitals with gonococci
  • preoperative prophylaxis in colorectal surgery

2. WHAT YOU NEED TO KNOW BEFORE YOU USE CEFOTAXIME INJECTION

Do not use Cefotaxime Injection:

  • if you are allergic (hypersensitive) to cefotaxime or any

    other cephalosporins

  • if you previously had acute and/or severe allergic

    reactions to penicillin or any other beta-lactam antibiotic

If given as an injection into the muscle:

Your doctor may consider it necessary to inject this medicine into a muscle. In this case, the doctor will add lidocaine to the injection to make it less painful. However, this method of administering the injection will not be suitable for everyone and should not be given:

  • to infants under 30 months
  • if you are allergic (hypersensitive) to lidocaine or other

    local anaesthetics of the amide type

  • if you have irregular heartbeat
  • if you have heart problems which can cause shortness of

    breath or ankle swelling

  • if you are receiving Cefotaxime Injection intravenously

    (directly into your bloodstream)

Please inform your doctor if one of these applies to you so that your doctor can decide on the form of application.

Warnings and precautions

Tell your doctor or healthcare professional if:

  • you have ever had an allergic or hypersensitive reaction

    to penicillin or other medicines from the penicillin family (beta-lactam-antibiotics)

  • experience skin reactions. Contact your doctor immediately • you suffer from severe allergies or asthma
  • you develop severe persistent (bloody) diarrhoea. You

    caused by the use of cefotaxime. In that case, the use of Cefotaxime Injection must be stopped immediately. Do not take medicines that reduce bowel movements • you have kidney problems

  • you are on a low-sodium (low salt) diet

    If any of these apply to you, your doctor may want to change your treatment or give you special advice.

    Cefotaxime Injection may cause you to become infected with organisms that are unsusceptible to antibiotics, so your doctor will monitor your condition. If you become infected,

    This medicine can alter the results of some blood and urine tests. If you are having blood tests (such as Coombs’ test) or urinary sugar tests (the Fehling’s type which test for reducing sugars) tell your doctor you are taking this medicine as this medicine may cause false positive results.

    Your doctor may decide to do tests on your blood if you are given Cefotaxime Injection for longer than 7 days.

    Other medicines and Cefotaxime Injection

    Please tell your doctor or healthcare professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

    Concomitant intake of:

    • other antibiotics (such as penicillins, aminoglycosides,

      tetracyclines, erythromycin and chloramphenicol) • diuretics (e.g. furosemide)

    • probenecid (for the treatment of gout and arthritis) may

      increase or decrease the effect of Cefotaxime Injection. Inform your doctor if you are in treatment with these medicines

concomitant use of cefotaxime. Therefore during treatment with Cefotaxime Injection additional contraceptive methods should be used.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

If you are pregnant or are planning to become pregnant, your doctor has to determine if a treatment with Cefotaxime Injection is suitable for you.

Cefotaxime Injection excretes in breast milk in low concentrations. Therefore it should not be used during breast-feeding.

Driving and using machines

The effect of cefotaxime on the ability to drive and use machines has not been investigated. However, this medicine may cause impairment of consciousness, abnormal movements and dizziness in some patients. If this happens, do not drive or use machines.

Important information about some of the ingredients of Cefotaxime Injection

This medicinal product contains 48 mg sodium per gram. To be taken into consideration by patients on a controlled sodium diet.

3. HOW TO USE CEFOTAXIME INJECTION

Cefotaxime Injection is normally given by a doctor or nurse. You should check with your doctor or healthcare professional if you are not sure.

Cefotaxime Injection should always be administered intravenously (in a vein) or intra muscular (in a muscle). The injection will always be administered by a doctor.

Dose, method of application and intervals between injections depend on the sensitivity of the micro-organism, the severity of your infection and your condition.

How much Cefotaxime Injection will be given?

Adults and adolescents (12 to 16-18 years) will usually be given 1 g every 12 hours. In severe infections, this may be increased up to 12 g per day, given in 3-4 doses. For infections caused by sensitive Pseudomonas species, daily doses of greater than 6 g will usually be required. "

Reconstitution:

From the calculated dose, determine the appropriate number of vials to be used. Add the recommended volume of reconstitution solution and shake well until the contents of the vial have dissolved completely.

INFORMATION FOR THE DOCTOR Cefotaxime 500 mg Injection and 1 g Injection or Infusion INFORMATION FOR THE HEALTH CARE PROFESSIONAL

Route of administration Reconstitution solution Diluent required Displacement volume

500 mg 1 g 500 mg 1 g

Intravenous or

intramuscular

injection Water for Injections Ph. Eur. 2 ml 4 ml

0.45 ml 0.9 ml

Intravenous

infusion

Water for Injections Ph. Eur.

Sodium Chloride Injection BP

5% Dextrose Injection BP

Dextrose and Sodium Chloride

Injection BP

Sodium lactate Injection BP

40-100 ml for 1-2 g of

Cefotaxime

Children: The dose will depend on the size of your body; the usual dose is 50-100 mg/kg/day in 2-4 divided doses. In very severe infections, doses of up to 200 mg/kg/day may be required.

Babies (0-27 days): The recommended dosage is 50 mg/ kg/day in 2-4 divided doses. In severe infections, doses of up to 150-200 mg/kg/day may be required.

Use in patients with kidney problems

If the condition of the kidneys is very poor (creatinine clearance of ≤ 5 ml/min), your doctor will reduce the dosage by half after you have received an initial normal dose.

If you think you have been given too much Cefotaxime Injection

This is not likely, as the injection is given to you by a doctor. If you feel bad after administration of the injection, please contact your doctor immediately.

If your doctor stops giving you Cefotaxime Injection

The doctor will continue treatment with Cefotaxime Injection until the infection treated is relieved.

If you have any further questions on the use of this product, ask your doctor.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Cefotaxime Injection can cause side effects, although not everybody gets them.

Very common side effects (affects more than 1 user in 10):

  • transient pain at the injection site

Uncommon side effects (affects 1 to 10 users in 1,000):

  • reduced amount of white blood cells or of blood platelets • reactions called “Jarisch-Herxhemier” which includes

    fever, shivering, headache and joint pain

  • convulsions
  • diarrhoea
  • changes in liver values
  • rash, itching and special skin rash named urticaria • impaired kidney function
  • fever

•

(thrombophlebitis)

Not known (frequency cannot be estimated from the available data):

  • infections with unsusceptible organisms

    (“Superinfections”)

  • decrease in the number of a type of white blood cells

    (neutropenia)

  • serious condition in which white blood cells decrease in

    number or disappear altogether (Agranulocytosis), sometimes also called ‘granulocytopenia’

  • low levels of red blood cells (anaemia)
  • anaphylactoid reactions (that may range from mild to

    severe, including a sudden, generalised allergic reaction that may lead to a life-threatening “anaphylactic” shock

    pulse])

  • severe allergic reactions as swelling of the face, throat,

    and lips (angiooedema)

  • bronchial spasms
  • headache and dizziness
  • brain disorders (e.g. impairment of consciousness,

    abnormal movements)

  • irregular heartbeat
  • feeling sick, vomiting
  • pain in the abdomen
  • a serious bacterial infection of your gut known as

    pseudomembranous colitis (including severe, persistent or bloody diarrhoea associated with abdominal pain or fever) • hepatitis, sometimes with jaundice

  • serious skin conditions such as Steven-Johnsons

    syndrome, erythema multiforme and toxic epidermal necrolysis

•

  • reactions to lidocaine if Cefotaxime Injection is given as a

    injection into a muscle

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed

    Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA yellow card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE CEFOTAXIME INJECTION

Your doctor or pharmacist is responsible for storing Cefotaxime Injection. They are also responsible for disposing of any unused Cefotaxime Injection correctly.

Keep this medicine out of the sight and reach of children.

Do not use Cefotaxime Injection after the expiry date which is stated on the vial and carton after EXP. The expiry date refers to the last day of that month.

Store the unopened vial below 25°C. Keep container in the outer carton.

Once the powder has been dissolved, the solution should be used immediately or stored at 2-8°C and discarded after 24 hours.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What Cefotaxime Injection contains

The active substance in Cefotaxime Injection is cefotaxime as the sodium salt. The total sodium (salt) content is approximately 24 or 48 mg respectively.

1 vial Cefotaxime Injection, 0.5 g contains 0.524 g cefotaxime sodium, corresponding to 500 mg cefotaxime.

1 vial Cefotaxime Injection, 1 g contains 1.048 g cefotaxime sodium, corresponding to 1 g cefotaxime.

There are no other ingredients.

What Cefotaxime Injection looks like and contents of the pack

Cefotaxime Injection is a white to slightly yellow powder in a colourless glass vial. It is supplied in 500 mg or 1 g vials with 1, 5, 10, 25 or 50 vials in a carton.

Not all pack sizes may be marketed

PL 42671/0004 - Cefotaxime 500 mg powder for solution for injection

PL 42671/0005 - Cefotaxime 1 g powder for solution for injection or infusion

Marketing Authorisation Holder:

Cox Pharmaceutical Ltd

Elscot House, Arcadia Avenue,

London N3 2JU, UK

Manufacturer:

IPG Pharma Ltd

Atrium Court

The Ring

Bracknell

RG12 1BW, UK

This lea et was last revised in Oct 2021

A326/UK/C

"

Prepared injections should be used immediately. Prepared infusion to be administered over 20-60 minutes. Cefotaxime is for single patient use only, discard any unused solution.

Reconstitute with:

Water for Injections Ph. Eur.

Sodium Chloride Injection BP

5% Dextrose Injection BP

Dextrose and Sodium Chloride Injection BP

Sodium lactate Injection BP

Metronidazole Infusion (500 mg/100 ml)

1% lidocaine/lignocaine (freshly prepared)

The reconstituted solution should be clear, do not use the solution if particles are present.

HA Approval Received by: Approval / Sign off by appointed representative

Verified by: Regulatory

Commercial

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 42671/0004

Last revision stated in the text: October 2021 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Cefotaxime 500 mg powder for solution for injection

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Cefotaxime
Strength 500 mg
Pharmaceutical form Powder for solution for injection
Appearance: White to slightly yellow powder
How is it taken Intravenous, Intramuscular
Excipients None.
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life Unopened : 24 months.
Reconstitution: Chemical and physical in-use stability has been demonstrated for 3 days at 2-8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions before use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Storage For the unopened product, do not store above 25°C. Keep the vial in the outer carton in order to protect from light. When reconstituted store at 2-8°C.
Drug group (ATC) Other Beta-Lactam Antibacterials
  1. J Antiinfectives for systemic use
    1. J01 Antibacterials for systemic use
      1. J01D Other beta-lactam antibacterials
        1. J01DD Third-generation cephalosporins
          1. J01DD01 cefotaxime
Marketing authorisation PL 42671/0004 (first authorised 8 November 2000)
Marketing authorisation holder Cox Pharmaceutical Ltd.
Codes BNF 05010201

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.